Showing results (191-200 of 216) with videos related to

Sort By:
Pageof 22
NPJ Precision Oncology|March 20, 2021
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancerG Griguolo, G Serna, T Pascual, et al.
ESMO Open|October 17, 2025
Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapyR Gómez-Bravo, B Walbaum, M Bergamino, et al.
ESMO Open|September 2, 2025
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trialT Pascual, G Villacampa, M Oliveira, et al.
European Journal of Neurology|October 10, 2018
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort studyJ Lorscheider, J Kuhle, G Izquierdo, et al.
ESMO Open|January 18, 2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancersF Lynce, O Martínez-Sáez, B Walbaum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)A Fernandez-Martinez, M Tanioka, S G Ahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJ Veeraraghavan, C De Angelis, R Mao, et al.
Journal of Mammary Gland Biology and Neoplasia|November 8, 2024
Gestational breast cancer: distinctive molecular and clinico-epidemiological featuresJ R de la Haba-Rodríguez, P Mínguez, F Rojo, et al.
ESMO Open|November 28, 2024
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational studyF Schettini, F Brasó-Maristany, T Pascual, et al.
ESMO Open|April 10, 2025
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center studyA Rodriguez-Hernandez, O Martínez-Sáez, F Brasó-Maristany, et al.
Pageof 22